Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety of UV1 Vaccination in Combination With Ipilimumab in Patients With Unresectable or Metastatic Malignant Melanoma

Trial Profile

Safety of UV1 Vaccination in Combination With Ipilimumab in Patients With Unresectable or Metastatic Malignant Melanoma

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 14 Sep 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs UV 1 (Primary) ; Granulocyte macrophage colony stimulating factor; Ipilimumab
  • Indications Malignant melanoma
  • Focus Adverse reactions
  • Sponsors Ultimovacs AS
  • Most Recent Events

    • 12 Sep 2022 Results published in the Media Release
    • 12 Sep 2022 According to an Ultimovacs AS media release, data from phase 1 part of this study presented in Journal of Translational Medicine.
    • 25 May 2022 According to an Ultimovacs AS media release, data from this study presented at the Journal for ImmunoTherapy of Cancer and was also presented as a poster at the Cancer Immunotherapy (CIMT) annual meeting.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top